Leerink, Quest Diagnostics and M&A
Equities research analysts at Leerink Partnrs cut their Q2 2025 earnings per share (EPS) estimates for Geron in a note issued ...
Hosted on MSN1d
Leerink Partners Upgrades Align Technology (ALGN)Fintel reports that on January 6, 2025, Leerink Partners upgraded their outlook for Align Technology (NasdaqGS:ALGN) from ...
LEXINGTON, Mass. and AMSTERDAM, Jan. 08, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing ...
Align Technology (NASDAQ:ALGN – Get Free Report) was upgraded by investment analysts at Leerink Partnrs from a “hold” rating ...
Clover Health Investments Corp (CLOV) stock saw a modest uptick, ending the day at $3.6 which represents a slight increase of $0.22 or 6.51% from the prior close of $3.38. The stock opened at $3.38 ...
Leerink keeps an Outperform rating and a $60 price target on Kymera Therapeutics (KYMR) while noting that the firm sees a ...
(Reuters) - Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of ...
CureVac BV (CVAC) stock saw a modest uptick, ending the day at $4.44 which represents a slight increase of $0.82 or 22.65% from the prior close of $3.62. The stock opened at $4.14 and touched a low of ...
https://www.tipranks.com/news/the-fly/iteos-therapeutics-price-target-lowered-to-19-from-31-at-wells-fargo Leerink analyst Christopher Liu lowered the firm’s price ...
LEXINGTON, Mass. and AMSTERDAM, Jan. 08, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback